<DOC>
	<DOCNO>NCT02116907</DOCNO>
	<brief_summary>This open-label , single-dose study healthy male subject . The study 2 phase : Pretreatment Treatment . The Pretreatment Phase last 21 day consist Screening Period Baseline Period , subject 's study eligibility determine baseline assessment conduct .</brief_summary>
	<brief_title>An Open-Label , Single-Dose Study Determine Metabolism Elimination 14C-Perampanel Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1 . Healthy male 18 55 year , inclusive , time informed consent 2 . Body mass index ( BMI ) 18 30 kg/m2 , inclusive , Screening 3 . Must successful vasectomy ( confirm azoospermia ) female partner must childbearing potential must practice highly effective contraception throughout study period 90 day study drug discontinuation . No sperm donation allow study period 90 day study drug discontinuation . 4 . Provide write informed consent 5 . Willing able comply aspect protocol Exclusion Criteria 1 . Participated 14C research study within 6 month Day2 . The total exposure previous study must within recommend level consider safe ( per 21 Code Federal Regulations [ CFR ] 361.1 ) 2 . Exposure clinically significant radiation within 12 month Day2 3 . Clinically significant illness require medical treatment within 8 week clinically significant infection require medical attention within 4 week dose</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Male Subjects</keyword>
</DOC>